ALX Oncology Holdings Inc. surged as positive clinical trial news fueled optimism, and stocks have been trading up by 11.73 percent.
Click Here for a Millionaire's POV on Trading ALXO
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Market Insights For Active Traders
- Fireside chat at the 2026 Jefferies Global Healthcare Conference puts ALX Oncology in front of a major institutional audience.
- Management will spotlight the clinical-stage pipeline, with emphasis on lead CD47 blocker evorpacept.
- EGFR-targeted ADC ALX2004 adds another key asset to the ALXO oncology story.
- Webcast access lets traders track any tone shift or new clinical detail in real time.
Weekly Update Jun 22 – Jun 26, 2026: On Sunday, June 28, 2026 ALX Oncology Holdings Inc. stock [NASDAQ: ALXO] is trending up by 11.73%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – neutral
ALX Oncology is a clinical-stage biotech with no commercial revenue and structurally negative profitability (ROE ~-74%, ROA ~-59%), typical for pre-revenue oncology platforms. Balance sheet strength is a clear positive: cash and short-term investments of ~$140M, working capital of ~$125M, current ratio ~7x, and minimal leverage (debt-to-equity ~0.06) imply at least several quarters of runway despite Q1 operating cash burn of ~$18.6M and net loss of ~$17.9M.
Technically, ALXO has shifted into a short-term bullish phase. The weekly sequence from 1.63 to 2.00+ shows a clean series of higher lows and strong follow-through, with the 2.00 level now emerging as near-term resistance turned support. Recent 5-minute candles show buyers absorbing supply above 1.75 with expanding volume on up-moves. A pragmatic trading level is 1.95–2.00: buy pullbacks into that zone with a stop near 1.75 and upside toward 2.40.
More Breaking News
- Anterix ATEX Jumps As Spectrum Gains Power Earnings Beat
- LCTX Edges Higher As Traders Focus On Tight Range Setup
- CANF Slides After Sharp Intraday Reversal Tests Support
- ServiceNow Stock Builds AI Momentum As Analysts Boost Targets
Near-term catalysts are primarily clinical and visibility-driven, with the Jefferies conference fireside chat spotlighting evorpacept and EGFR-targeted ADC ALX2004. Relative to biotech peers, ALXO offers de-risked balance sheet but remains binary on trial data versus sector indices that have broader diversification. I assign a cautiously constructive outlook with technical support at 1.75, strong support at 1.60, and resistance near 2.40; 12–18 month fair-value trading target: 2.75.
Quick Financial Overview
ALX Oncology Holdings Inc. is trading in a clear short-term upswing, with the weekly chart showing a move from $1.63 to $2.00 over the latest data window. That is a meaningful percentage gain in a thinly priced biotech, and it signals fresh interest building ahead of the Jefferies conference appearance. The intraday 5-minute candle shows a spike from $1.79 to $2.13 before settling near $2.04, which tells you there was aggressive buying followed by some profit-taking but no complete reversal.
On the fundamentals side, ALX Oncology remains a clinical-stage name burning cash. The latest quarterly net loss is about $17.9M, or -$0.17 per share, driven mainly by research expense of roughly $13.6M and general and administrative costs of about $5.4M. Operating cash flow is around -$18.6M, with free cash flow near -$18.7M, so this is still very much a development-stage story, not a profit story.
Balance sheet strength is a critical piece for ALXO traders. The company reports about $140.3M in cash and short-term investments and working capital of roughly $125.4M, against total liabilities of only about $27.0M. Leverage is low, with debt-to-equity around 0.06 and a current ratio above 7, which gives ALX Oncology room to keep funding evorpacept and ALX2004 without immediate financing pressure. Valuation metrics like price-to-book near 1.51 and deeply negative returns on capital simply confirm this is a high-risk, high-upside biotech setup where pipeline progress drives the chart.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.